SCHEMBL23630479

SCHEMBL23630479

Nc1nnc(Cl)cc1N1CCN(c2cc(CCC(=O)O)ccn2)CC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AOC3 Q16853 1/20 0.40
▸ FFAR1 O14842 2/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ GRM5 P41594 3/20 0.37
▸ PLA2G10 O15496 1/20 0.37
▸ PLA2G2A P14555 1/20 0.37
▸ PLA2G5 P39877 1/20 0.37
▸ KDM4E B2RXH2 1/20 0.37
▸ CYP3A4 P08684 1/20 0.37
▸ CYP2C9 P11712 1/20 0.37
▸ HPGD P15428 1/20 0.37
▸ RECQL P46063 1/20 0.37
▸ HSD17B10 Q99714 1/20 0.37
▸ MAP4K4 O95819 1/20 0.36
▸ ME2 P23368 2/20 0.35
▸ ME1 P48163 2/20 0.35
▸ ME3 Q16798 2/20 0.35
▸ ITGB3 P05106 1/20 0.34
▸ ITGA2B P08514 1/20 0.34
▸ PIM2 Q9P1W9 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29943898 1.00 AOC3 (0.40) AOC3FFAR1ALDH1A1GRM5PLA2G10
SCHEMBL23630379 0.89 GABRP (0.45) AOC3GRM5GPR52KLKB1PIK3CA
SCHEMBL29944108 0.89 GABRP (0.45) AOC3GRM5GPR52KLKB1PIK3CA
SCHEMBL29943895 0.88 AOC3 (0.40) AOC3ALDH1A1GRM5GPR52KLKB1
SCHEMBL23630325 0.88 AOC3 (0.40) AOC3ALDH1A1GRM5GPR52KLKB1
SCHEMBL23630405 0.81 PIK3CA (0.54) ALDH1A1KDM4EHSD17B10PIK3CA
SCHEMBL29943886 0.81 PIK3CA (0.54) ALDH1A1KDM4EHSD17B10PIK3CA
SCHEMBL23630466 0.75 PIK3CA (0.47) ALDH1A1KDM4EHPGDPIK3CA
SCHEMBL29944012 0.75 PIK3CA (0.47) ALDH1A1KDM4EHPGDPIK3CA
SCHEMBL23630351 0.74 PIK3CA (0.41) ALDH1A1GRM5PIK3CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230091042-A1 SMARCA2-VHL DEGRADERS AMGEN INC. (US) 2023-03-23 — — US disclosed
EP-4087658-A1 SMARCA2-VHL DEGRADERS Amgen Inc. (US) 2022-11-16 — — EP disclosed
WO-2021142247-A1 SMARCA2-VHL DEGRADERS AMGEN INC. (US) 2021-07-15 — — WO disclosed
WO-2021142247-A1 SMARCA2-VHL DEGRADERS AMGEN INC. (US) 2021-07-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230091042-A1 SMARCA2-VHL DEGRADERS VHL, SMARCC2, SMARCC1 AOC3 4259/4885FFAR1 4181/4885ALDH1A1 1744/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback